Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis

Molecular Therapy(2022)10.1016/j.ymthe.2022.07.008Source: DataRank Database

Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis is a research paper published in Molecular Therapy (2022). On theSindex it has a DataRank of 0. It has been cited 29 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access29 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 3.13)OA: greenTopics (43)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Michelle N. Karl,Wentao Wang ORCID,Bartholomew Starich ORCID,Haotian Tan ORCID,Ashley Kiemen ORCID

Live enrichment

PubMed:35841152 PMC:PMC9637575 OpenAlex:https://openalex.org/W4285677998

National Institutes of Health

Grant: U54CA143868

National Institutes of Health

Grant: U01AG060903

NCI NIH HHS

Grant: U54 CA210173

National Institutes of Health

Grant: 5U01AG060903-04

Validation of Nuclear Morphology as a Biomarker of Aging and Aging-Related Phenotypes

National Institutes of Health

Grant: 1U54CA143868-01

Center for Cancer Physics

National Science Foundation

FWCI

3.13

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

greenLicense: CC BY NC ND

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9637575

publisherhttps://api.elsevier.com/content/article/PII:S1525001622004294?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525001622004294?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ymthe.2022.07.008

Fields of Study

Monoclonal and Polyclonal Antibodies ResearchImmunotherapy and Immune ResponsesAdvanced Biosensing Techniques and Applications0301 basic medicine0303 health sciences03 medical and health sciencesHumansAnimalsAntibodies, BispecificInterleukin-6Triple Negative Breast NeoplasmsAntibodies, MonoclonalCell Movement

MeSH Terms

AnimalsAntibodies, MonoclonalCell MovementHumansInterleukin-6Antibodies, BispecificTriple Negative Breast Neoplasms

Keywords

Cancer researchMetastasisMonoclonal antibodyAntibodyCancerMetastatic breast cancerCancer cellInterleukin 2Breast cancerImmunologyMedicineBiologyCytokineInternal medicineInterleukinscell migrationInterleukin-6Cell MovementAntibodies, BispecificHumansAnimalsAntibodies, MonoclonalTriple Negative Breast Neoplasms

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis

FAIR Checklist

Authors (14)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)